POR CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Por um escritor misterioso
Descrição
CVM-1118 (foslinanib) is a phosphoric ester compound selected from 2-phenyl-4-quinolone derivatives. The NCI 60 cancer panel screening showed CVM-1125, the major active metabolite of CVM-1118, to exhibit growth inhibitory and cytotoxic effects at nanomolar range. CVM-1118 possesses multiple bioactivities, including inducing cellular apoptosis, cell cycle arrest at G2/M, as well as inhibiting vasculogenic mimicry (VM) formation. The TNF receptor associated protein 1 (TRAP1) was identified as the binding target of CVM-1125 using nematic protein organization technique (NPOT) interactome analysis. Further studies demonstrated CVM-1125 reduced the protein level of TRAP1 and impeded its downstream signaling by reduction of cellular succinate levels and destabilization of HIF-1α. The pharmacogenomic biomarkers associated with CVM-1118 were also examined by Whole Genome CRISPR Knock-Out Screening. Two hits (STK11 and NF2) were confirmed with higher sensitivity to the drug in cell knock-down experiments. Biological assays indicate that the mechanism of action of CVM-1118 is via targeting TRAP1 to induce mitochondrial apoptosis, suppress tumor cell growth, and inhibit vasculogenic mimicry formation. Most importantly, the loss-of-function mutations of STK11 and NF2 are potential biomarkers of CVM-1118 which can be applied in the selection of cancer patients for CVM-1118 treatment. CVM-1118 is currently in its Phase 2a clinical development.
4-Hydroxy-2-quinolones: syntheses, reactions and fused heterocycles
Frontiers The development of cancers research based on mitochondrial heat shock protein 90
Antiangiogenic compounds currently approved by the USA Food and Drug
Relationship between complex size and essentiality. a, fraction of
Cytotoxic activity of anthracyclins correlates with ER stress
Lkb1 (Qiagen), Bioz
Full article: Developing our knowledge of the quinolone scaffold and its value to anticancer drug design
Tumor cell vascular mimicry: Novel targeting opportunity in melanoma. - Abstract - Europe PMC
A complex-level interaction network. a, a fragment of our Complex- Net
Tumor cell vascular mimicry: Novel targeting opportunity in melanoma. - Abstract - Europe PMC
1) Tumor microenvironment and VM: TAFs (tumor-associated fibroblasts)
de
por adulto (o preço varia de acordo com o tamanho do grupo)
